Hangzhou TianMuShan Pharmaceutical Enterprise Co (600671) Fair Value & Analysis
Healthcare · CN · Market cap 2.0B CNY
Fair value as of: Jun 24, 2026
Analysis
Hangzhou TianMuShan Pharmaceutical Enterprise Co (600671) currently trades at ¥18.34, while our model-based Fair Value estimate is ¥2.57 — implying the stock looks roughly 86.0% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared slices of traditional Chinese medicine. In addition, the company operates Chinese medicine clinic; provision of traditional chinese medicine clinic, software development, remote health management, commercial complex management, and internet information services; food business; and sale of health food products. The company was founded in 1958 and is headquartered in Hangzhou, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co (600671) undervalued?
What is the fair value of 600671?
What is the quality score of 600671?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.